Quinaglute, Nuedexta(quinidine gluconate)
Cardioquin, Cin-quin, Duraquin, Nuedexta, Quinact, Quinaglute, Quinalan, Quinatime, Quinidex, Quinora (quinidine gluconate) is a small molecule pharmaceutical. Quinidine gluconate was first approved as Quinaglute on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, and cardiac arrhythmias in the USA. It has been approved in Europe to treat neurobehavioral manifestations. It is known to target potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 5, equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily H member 5, and potassium voltage-gated channel subfamily H member 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Nuedexta (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dextromethorphan hydrobromide
+
Quinidine sulfate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NUEDEXTA | Avanir Pharmaceuticals | N-021879 RX | 2010-10-29 | 1 products, RLD, RS |
Quinidine gluconate
Quinidine polygalacturonate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CARDIOQUIN | Pharmaceutical Research Associates Inc | N-011642 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Quinidine sulfate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
QUINIDEX | WYETH PHARMS INC | N-012796 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
nuedexta | New Drug Application | 2022-11-30 |
quinidine gluconate | ANDA | 2021-12-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
atrial flutter | EFO_0003911 | D001282 | — |
cardiac arrhythmias | EFO_0004269 | D001145 | I49.9 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pseudobulbar palsy | D020828 | EFO_1001131 | — | — | 1 | 3 | — | 4 | |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 1 | 1 | — | 3 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 1 | — | 2 |
Traumatic brain injuries | D000070642 | S06 | — | — | 1 | 1 | — | 2 | |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | 1 | — | 2 |
Dementia | D003704 | F03 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 4 | — | — | 4 |
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | 1 | — | — | 3 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | — | — | 3 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 3 | — | — | 3 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
Ventricular fibrillation | D014693 | EFO_0004287 | I49.01 | — | — | 2 | — | — | 2 |
Huntington disease | D006816 | G10 | — | — | 1 | — | — | 1 | |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
Treatment-resistant depressive disorder | D061218 | — | 1 | — | — | — | 1 | ||
Dyskinesias | D020820 | G24 | — | 1 | — | — | — | 1 | |
Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 1 | — | — | — | 1 |
Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 8 | — | — | — | — | 8 | ||
Hepatitis b | D006509 | 1 | — | — | — | — | 1 | ||
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Constipation | D003248 | HP_0002019 | K59.0 | 1 | — | — | — | — | 1 |
Covid-19 | D000086382 | U07.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | QUINIDINE GLUCONATE |
INN | — |
Description | Quinidine is a cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy. It has a role as an alpha-adrenergic antagonist, an antimalarial, an anti-arrhythmia drug, a sodium channel blocker, a muscarinic antagonist, a potassium channel blocker, a P450 inhibitor, an EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor, an EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor and a drug allergen. It derives from a hydride of a cinchonan. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
Identifiers
PDB | — |
CAS-ID | 56-54-2 |
RxCUI | 9068 |
ChEMBL ID | CHEMBL1200437 |
ChEBI ID | 27502 |
PubChem CID | 441074 |
DrugBank | DB00908 |
UNII ID | — |
Target
Agency Approved
No data
Alternate
KCNA7
KCNA7
KCNA5
KCNA5
SLC29A4
SLC29A4
KCNH5
KCNH5
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNA7
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily A member 7
Protein synonyms
potassium channel, voltage gated shaker related subfamily A, member 7, potassium voltage-gated channel, shaker-related subfamily, member 7, voltage-dependent potassium channel Kv1.7, voltage-gated potassium channel KCNA7, Voltage-gated potassium channel subunit Kv1.7
Uniprot ID
Mouse ortholog
Kcna7 (16495)
potassium voltage-gated channel subfamily A member 7 (Q17ST2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,932 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,802 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more